- Quote, Chart, News
- Snapshot
- Company Report
- Quotes
- Charts
- Key Developments
Recent News- Research
- SEC Filings
- Advisor FYI
- CAPS
- StockScouter
- Earnings Estimates
- Analyst Ratings
- Financial Results
- Insider Trading
- Ownership
- Message Board
- Guided Research
- Research Wizard
- Find Stocks
- Stock Screener
- Stock Power Searches
- Top-Rated Stocks
- Related Links
- Quote Watchlist
- Expert Picks
- E-mail & Alerts
- IPO Center
- Message Boards
- Capital Gains Analysis
News resources
| Wal-Mart Stores Inc (WMT) | 44 stories... |
| Google Inc (GOOG) | 42 stories... |
| Citigroup Inc (C) | 38 stories... |
| Bank of America Corp (BAC) | 36 stories... |
| Amazon.com Inc (AMZN) | 35 stories... |
| advertisement |
Genzyme Corp: All Recent News
- Shire applies for Euro approval of Gaucher drug 8:50 AM
- BOSTON (MarketWatch) -- Shire plc said early Tuesday that it has applied for European marketing approval of its drug velaglucerase alfa, a treatment for the rare genetic disorder Gaucher disease. The product is also awaiting approval in the U.S. If approved, the drug would compete against Genzyme Corp.'s flagship product Cerezyme. A third company, Israel's Protalix BioTherapeutics is also finishing development on a drug to treat the disorder. At MarketWatch
- Top Takes From RealMoney 11/23/2009
- Here's what some of our market pros are saying and playing. At TheStreet.com
- Wall Street's 10 Favorite Stocks Right Now 11/20/2009
- Here they are. Now, are they the best bets for your money? At Motley Fool
- Biotech Stock Mailbag: FDA Playbook 11/20/2009
- Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process. At TheStreet.com
- Now's a Great Time to Invest -- So Don't Blow It Like This 11/19/2009
- Rethink the way you invest in mutual funds. ... At Motley Fool
- This Stock Is a Train Wreck 11/19/2009
- Genzyme's string of missteps has investors nervous. At Motley Fool
- Genzyme: Analysts' Upgrades, Downgrades 11/19/2009
- See who made what calls. At TheStreet.com
- Drug Lowers Cholesterol; Stock Follows 11/18/2009
- ISIS has a hard time at AHA despite good efficacy data. At Motley Fool
- Genzyme Drops Kidney-Drug Plans Amid Pileup of Bad News 11/18/2009
- ... At Wall Street Journal
- UPDATE 2-Genzyme negative news continues; stops drug trial 11/18/2009
- ... At Thomson Reuters
- Another Genzyme Drug Goes Kaboom: BioBuzz 11/18/2009
- Company halts development of kidney disease drug following poor test results. At TheStreet.com
- Market Report -- In Play (GENZ) 11/18/2009
- Genzyme reported results of a phase 2/3 study of its advanced phosphate binder; did not show a significant improvement in phosphate lowering Co reported results of a phase 2/3 study of its advanced... Briefing.com
- Genzyme Ends Plan for Stronger Renvela 11/18/2009
- ... At Wall Street Journal
- Genzyme ends development of Renvela successor 11/18/2009
- CAMBRIDGE, Mass. (AP) - Genzyme Corp. said Wednesday it is canceling development of a successor to its kidney treatment Renvela, as the new drug did not work much better than Renvela. Associated Press
- Genzyme Announces Results of Phase 2/3 Trial of Advanced... 11/18/2009
- Genzyme Corporation (Nasdaq: GENZ) today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered... Business Wire
- More News
- Market Report
- News by Symbol
- Today's Investing Articles
- Breaking News
- News by Topic
- News by Industry
- MSNBC News
- Data providers
- Copyright © 2009 Thomson Reuters. Click for Restrictions.
- Quotes supplied by Interactive Data Real-Time Services.